IDEXX Laboratories (IDXX) is trading higher today (up roughly 3%) after reporting first-quarter 2026 results and boosting its full-year guidance. The company posted Q1 revenue of $1.141 billion (up 14% reported, 11% organic) and EPS of $3.47 (up 17% reported, 15% comparable), and management lifted 2026 revenue and earnings targets.

IDEXX increased 2026 revenue guidance to $4.675 billion–$4.760 billion, a $42 million lift at the midpoint. The company also raised its 2026 EPS outlook to $14.45–$14.90, citing stronger revenue expectations and margin expansion (with updated foreign-exchange assumptions), partially offset by a loss on an equity investment.

Strength was led by the Companion Animal Group, where diagnostics recurring revenue rose 14% reported and 11% organic, including 11% U.S. growth and 21% reported growth internationally. IDEXX highlighted improved commercial execution, volume gains, net customer adds, and premium instrument installed-base expansion; the quarter also included 1,100 IDEXX inVue Dx placements, helping capital instrument revenue accelerate.

Management pointed to modestly improving clinical visit trends and continued momentum in newer offerings such as IDEXX Cancer Dx and the inVue Dx rollout (including Fine Needle Aspiration in a controlled launch). Investors will likely focus on whether U.S. visit pressure continues to ease, how fast utilization grows on the expanding installed base, and whether operating-margin expansion holds as the company keeps investing in R&D, commercial capabilities, and software.